IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study

被引：0
|
作者：
Liu, Rujiao
Hu, Xichun
Song, Zhengbo
Zhang, Jian
Jin, Jianan
Gao, Shuiping
Sun, Yuping
Zhang, Yan
Gao, Shegan
Jia, Ruinuo
Jing, Deqiang
Xu, Yu
Wang, Zhenjiu
Lu, Qiying
Tian, Wenzhi
Cheng, Xiangdong
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Shandong Prov Inst Canc Prevent & Treatment, Jinan, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[5] ImmuneOnco Biopharmaceut Shanghai Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14506
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Jeffrey R. Infante
    Roger B. Cohen
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Patricia M. LoRusso
    Investigational New Drugs, 2017, 35 : 576 - 588
  • [32] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    Lockhart, A. Craig
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Wang-Gillam, Andrea
    Moseley, Jennifer L.
    Barber, Stephanie L.
    Lane, Alex R.
    Wack, Claudine
    Kassalow, Laurent
    Dedieu, Jean-Francois
    Mita, Alain C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245
  • [33] Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Isambert, Nicolas
    Freyer, Gilles
    Zanetta, Sylvie
    You, Benoit
    Fumoleau, Pierre
    Falandry, Claire
    Favier, Laure
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Ziti-Ljajic, Samira
    Trillet-Lenoir, Veronique
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1743 - 1750
  • [34] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [35] Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
    Strickler, John H.
    LoRusso, Patricia
    Salgia, Ravi
    Kang, Yoon-Koo
    Yen, Chia Jui
    Lin, Chia-Chi
    Ansell, Peter
    Motwani, Monica
    Wong, Shekman
    Yue, Huibin
    Wang, Lan
    Reilly, Edward
    Afar, Daniel
    Naumovski, Louie
    Ramanathan, Ramesh K.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (05) : 1210 - 1217
  • [36] A phase I dose-escalation and pk study of continuous oral rucaparib in patients with advanced solid tumors
    Flynn, M.
    Shapiro, G.
    LoRusso, P.
    Kristeleit, R.
    Patel, M.
    Infante, J.
    Giordano, H.
    Borrow, J.
    Jaw-Tsai, S.
    Burris, H., III
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185
  • [37] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17
  • [38] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [39] A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors
    Desai, Jayesh
    Markman, Ben
    Sandhu, Shahneen Kaur
    Gan, Hui Kong
    Friedlander, Michael
    Tran, Ben
    Meniawy, Tarek
    Boolell, Vishal
    Colyer, Duncan
    Norris, Christie
    Ameratunga, Malaka
    Yang, Jason
    Li, Kang
    Wang, Lai
    Luo, Lusong
    Qin, Zhen
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors
    Prenen, H.
    Kyi, C.
    Van Lancker, G.
    Patel, S. P.
    Mittag, D.
    Weaver, A.
    Bol, K.
    Stalbovskaya, V.
    Pulini, J.
    Zhou, G.
    Dong, Z.
    Asatiani, E.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1436 - S1436
12345